The Kennedy Trust for Rheumatology Research

The Trust's funding combines two primary sources. Ongoing royalty income derives from foundational intellectual property on anti-TNF therapies — the biologic drug class that includes Remicade and Humira — which the Trust has successfully defended in multiple jurisdictions. The Trust also maintains a UK commercial real estate endowment, with holdings in the Savills Charity Property Fund, Mayfair Capital PITCH fund, and CCLA COIF Charities Property Fund.

The Kennedy Institute of Rheumatology, originally an independent research center established by the Trust, is now part of the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences at the University of Oxford. The institute remains a primary recipient of Kennedy Trust research funding and operates as a world-class center for inflammation and immunology research.

The Trust's investment governance sits with its Board of Trustees, chaired by Professor Michael Patton. Day-to-day executive management falls to CEO Dr. Stephen Simpson. The endowment portfolio allocations to pooled UK property funds suggest an external-manager model for real assets, though the Trust does not publicly detail the full composition of its investment committee or the specific mandates given to external advisors.

The Kennedy Trust holds foundational patents underpinning anti-TNF monoclonal antibody therapies, the first biologic drugs approved for rheumatoid arthritis and later for inflammatory bowel disease, psoriasis, and other autoimmune conditions. This patent estate generated substantial royalty income from blockbuster drugs marketed by Johnson & Johnson, AbbVie, and others, and the Trust has litigated globally to enforce those rights against biosimilar entrants.

Through its membership in the Association of Medical Research Charities (AMRC), the Trust adheres to the UK sector's peer-review and funding standards. The Arthritis Therapy Acceleration Programme (A-TAP) functions as a collaborative translational vehicle, partnering with academic institutions and biotech firms rather than operating as a co-investment pool alongside peer charities in the traditional venture-capital sense.

Publicly identified holdings are concentrated in UK commercial real estate through pooled charity property funds managed by Savills, Mayfair Capital, and CCLA. The Trust's overall endowment composition — including any allocations to public equities, fixed income, or alternatives beyond real estate — is not publicly disclosed in detail.

The Trust is registered as a UK charity with a board of trustees providing fiduciary oversight. Professor Michael Patton chairs the board, and Dr. Stephen Simpson is CEO. As an AMRC member, the Trust follows the association's governance framework for research grant peer review and financial disclosure, though its total trustee count and committee structures are not publicly detailed.